<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0187-8433</journal-id>
<journal-title><![CDATA[Revista de la Asociación Mexicana de Medicina Crítica y Terapia Intensiva]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Asoc. Mex. Med. Crít. Ter. Intensiva]]></abbrev-journal-title>
<issn>0187-8433</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica y Terapia Intensiva A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0187-84332016000400230</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Precisión diagnóstica de prueba de estrés con furosemida para predicción de daño renal agudo severo]]></article-title>
<article-title xml:lang="en"><![CDATA[Diagnostic accuracy of the stress test with furosemide to predict of severe acute kidney injury]]></article-title>
<article-title xml:lang="pt"><![CDATA[Acurácia diagnóstica do teste de estresse com furosemida para a previsão de lesão renal aguda grave]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vega Martínez]]></surname>
<given-names><![CDATA[Diana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguirre Ávalos]]></surname>
<given-names><![CDATA[Guadalupe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chávez Iñiguez]]></surname>
<given-names><![CDATA[Jonathan Samuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Colunga Lozano]]></surname>
<given-names><![CDATA[Luis Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Estrada Gil]]></surname>
<given-names><![CDATA[Flavio César]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Guadalajara Hospital Regional de Guadalajara Valentín Gómez Farías ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2016</year>
</pub-date>
<volume>30</volume>
<numero>4</numero>
<fpage>230</fpage>
<lpage>234</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0187-84332016000400230&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0187-84332016000400230&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0187-84332016000400230&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  Diversos factores se han asociado a la presencia de daño renal agudo (DRA) en el paciente crítico, por lo cual se ha intentado implementar pruebas para determinar el funcionamiento y comportamiento de la función renal. La prueba de estrés con furosemida (PEF) es una estrategia sencilla y accesible en nuestro entorno para este fin. El presente estudio evalúa el rendimiento diagnóstico de la PEF en la progresión a daño renal agudo severo.  Métodos:  Mediante una cohorte prospectiva de septiembre de 2014 a septiembre de 2015 se evaluaron pacientes con daño renal agudo con KDIGO 1 y 2; previo a la PEF se determinó el estado de volemia por ultrasonografía enfocada y se procedió a administrar 1 mg/kg de furosemida en dosis única. Se definió como prueba positiva una diuresis &gt; 200 mL en las dos horas posteriores. Se dio seguimiento a la diuresis durante seis horas, la progresión a KDIGO 3, la necesidad de terapia de sustitución renal (TSR) y la mortalidad.  Resultados:  Se identificaron 20 pacientes con daño renal agudo KDIGO 1 y 2, para el análisis se clasificaron en respondedores (grupo R) y no respondedores (grupo NR) a la prueba. El grupo de los no respondedores estuvo compuesto de cuatro pacientes que presentaban correlación con progresión a KDIGO 3 y terapia de sustitución renal, p = 0.003 y p = 0.013, respectivamente; se documentó un área bajo la curva (ROC) de 0.83 (IC95% 0.60-0.96) y 0.84 (IC95% 0.61-0.96), no se observó asociación a mortalidad.  Conclusiones:  La PEF predice de manera adecuada el comportamiento de la función renal; existe concordancia con otros estudios pero se requiere una mayor población para corroborar los datos antes mencionados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Several factors are associated with the presence of acute kidney injury (AKI) in critical ill patients, that is the reason because many authors have attempted to develop diagnostic tests to determine the performance and behavior of renal function. The furosemide stress test (FST) is an easy and accessible strategy in our environment for this purpose. This study evaluated the diagnostic performance of the FST in the development of AKI stage 3.  Methods:  Through a prospective cohort (September 2014 to September 2015) we evaluated patient whit AKI stages 1 and 2; previously to the FST, volume status was determined by focused ultrasound and proceeded to administer 1 mg / kg single dose of furosemide. Positive test was defined as a urine output &gt; 200 ml in two hours later. We followed for six hours diuresis, progression to KDIGO 3, the need for renal replacement therapy (RRT) and mortality.  Results:  20 patients with AKI KDIGO 1 and 2 were identified, for the analysis they were classified in responders (R) and non-responders group (NR) to the test. NR group was formed by 4 patients who represented a correlation with progression KDIGO 3 and RRT, p = 0.003 and p = 0.013 respectively; it was documented an area under the curve (ROC) of 0.83 (95% CI 0.60 to 0.96) and 0.84 (95 % 0.61 to 0.96), no association was found with mortality.  Conclusions:  FST adequately predicts the behavior of renal function; this is consistent with other studies but a bigger study population is required to corroborate the accuracy of the data mentioned above.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  Vários fatores estão sendo associados com a presença de lesão renal aguda (LRA) em pacientes em estado crítico, por esse motivo procura-se implementar testes para determinar o desempenho e o comportamento da função renal. O teste de estresse com furosemida (TEF) é uma estratégia simples e acessível para este fim. Este estudo avaliou o desempenho diagnóstico do TEF na progressão do LRA grave.  Métodos:  Usando uma coorte prospectiva do mês de setembro de 2014 a setembro de 2015, foram avaliados os pacientes com LRA com KDIGO 1 e 2; prévio ao TEF se determinou o estado da volemia por ultrassom focalizado e se procedeu a administrar uma dose única de 1 mg/kg de furosemida. O teste positivo foi definido com uma diurese &gt; 200 mL posterior a 2 horas. Foi feito um controle: da diurese durante 6 horas, da progressão à KDIGO 3, da necessidade de terapia de substituição renal e mortalidade.  Resultados:  Foram identificados 20 pacientes com LRA KDIGO 1 e 2, para análise se classificaram como respondedores (R) e não respondedores (NR) ao teste. O grupo NR foi formado por pacientes que apresentaram correlação com a progressão para KDIGO 3 de p = 0.003 e para TSR de p = 0.013; se documentou uma área sob a curva (ROC) de 0.83 (IC 95% 0.60-0.96) e 0.84 (IC 95% 0.61-0.96)respectivamente. Não foi encontrado uma associação com a mortalidade.  Conclusões:  A TEF prevê adequadamente o comportamento da função renal; existe uma concordância com outros estudos, mas é necessária uma população maior para corroborar os dados antes mencionados.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Furosemida]]></kwd>
<kwd lng="es"><![CDATA[daño renal agudo]]></kwd>
<kwd lng="es"><![CDATA[terapia de sustitución renal]]></kwd>
<kwd lng="en"><![CDATA[Furosemide]]></kwd>
<kwd lng="en"><![CDATA[acute kidney injury]]></kwd>
<kwd lng="en"><![CDATA[renal replacement therapy]]></kwd>
<kwd lng="pt"><![CDATA[Furosemida]]></kwd>
<kwd lng="pt"><![CDATA[lesão renal aguda]]></kwd>
<kwd lng="pt"><![CDATA[terapia de substituição renal]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liaño]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pascual]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of acute renal failure: a prospective, multicenter community-based study. Madrid Acute Renal Failure Study Group]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>1996</year>
<volume>50</volume>
<page-range>811-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cartin-Ceba]]></surname>
<given-names><![CDATA[R1]]></given-names>
</name>
<name>
<surname><![CDATA[Kashiouris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Plataki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kor]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gajic]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for development of acute kidney injury in critically ill patients: a systematic review and meta-analysis of observational studies]]></article-title>
<source><![CDATA[Crit Care Res Pract]]></source>
<year>2012</year>
<numero>2012</numero>
<issue>2012</issue>
<page-range>691013</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer-Nadal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Piccinni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Chawla]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Alessandri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilization of small changes in serum creatinine with clinical risk factors to assess the risk of AKI in critical ill adults]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2014</year>
<volume>9</volume>
<page-range>663-72</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chawla]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Davison]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Brasha-Mitchell]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Koyner]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Arthur]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development a standardization of a furosemide stress test to predict the Severity of Acute Kidney Injury]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2013</year>
<volume>17</volume>
<page-range>R207</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>KDIGO</collab>
<source><![CDATA[Clinical Practice Guideline for Acute Kidney Injury]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chawla]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Dommu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shih]]></surname>
<given-names><![CDATA[s]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Urinary sediment cast scoring index for acute kidney injury a pilot study]]></article-title>
<source><![CDATA[Nephron Clin Pract]]></source>
<year>2008</year>
<volume>110</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>c145-50</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knaus]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Draper]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmerman]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[APACHE II a severity of disease classification system]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>1985</year>
<volume>13</volume>
<page-range>881-29</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Takala]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Willatts]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[De Mendoça]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bruining]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>1996</year>
<volume>22</volume>
<page-range>707-10</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Power]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benefits and risk of furosemide in acute kidney injury]]></article-title>
<source><![CDATA[Anaesthesia]]></source>
<year>2010</year>
<volume>65</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>283-93</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heyman]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Spokes]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Brezis]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Loop diuretics reduce hypoxic damage to proximal tubules of the isolated perfused rat Kidney]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>1994</year>
<volume>45</volume>
<page-range>981-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karvellas]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Farhat]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Sajjad]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mogensen]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Wald]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2011</year>
<volume>15</volume>
<page-range>R72</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
